[HTML][HTML] Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer …
M Nicoś, A Rolska-Kopińska, P Krawczyk… - Archives of Medical …, 2021 - ncbi.nlm.nih.gov
Results Patients with C/C genotype in rs13695 of the TOP2A gene had significantly lower
risk of neutropenia during chemotherapy than C/T heterozygous patients (p= 0.02, χ²= 5.51 …
risk of neutropenia during chemotherapy than C/T heterozygous patients (p= 0.02, χ²= 5.51 …
[PDF][PDF] Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients
M Nicoś, A Rolska-Kopińska, P Krawczyk, A Grenda… - 2020 - pdfs.semanticscholar.org
Introduction: The main treatment regimen for small cell lung cancer (SCLC) involves
platinum-based chemotherapy (cisplatin or carboplatin) and etoposide. Single nucleotide …
platinum-based chemotherapy (cisplatin or carboplatin) and etoposide. Single nucleotide …
Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients
M Nicoś, A Rolska-Kopińska… - … of medical science …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction The main treatment regimen for small cell lung cancer (SCLC) involves platinum-
based chemotherapy (cisplatin or carboplatin) and etoposide. Single nucleotide …
based chemotherapy (cisplatin or carboplatin) and etoposide. Single nucleotide …
[PDF][PDF] Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients
M Nicoś, A Rolska-Kopińska, P Krawczyk, A Grenda… - 2020 - termedia.pl
Introduction: The main treatment regimen for small cell lung cancer (SCLC) involves
platinum-based chemotherapy (cisplatin or carboplatin) and etoposide. Single nucleotide …
platinum-based chemotherapy (cisplatin or carboplatin) and etoposide. Single nucleotide …
[HTML][HTML] Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer …
M Nicoś, A Rolska-Kopińska… - Archives of …, 2021 - archivesofmedicalscience.com
Results: Patients with C/C genotype in rs13695 of the TOP2A gene had significantly lower
risk of neutropenia during chemotherapy than C/T heterozygous patients (p= 0.02, χ²= 5.51 …
risk of neutropenia during chemotherapy than C/T heterozygous patients (p= 0.02, χ²= 5.51 …
Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients.
M Nicoś, A Rolska-Kopińska, P Krawczyk… - Archives of Medical …, 2020 - europepmc.org
Results Patients with C/C genotype in rs13695 of the TOP2A gene had significantly lower
risk of neutropenia during chemotherapy than C/T heterozygous patients (p= 0.02, χ²= 5.51 …
risk of neutropenia during chemotherapy than C/T heterozygous patients (p= 0.02, χ²= 5.51 …
[HTML][HTML] Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer …
M Nicoś, A Rolska-Kopińska… - Archives of …, 2021 - archivesofmedicalscience.com
Results: Patients with C/C genotype in rs13695 of the TOP2A gene had significantly lower
risk of neutropenia during chemotherapy than C/T heterozygous patients (p= 0.02, χ²= 5.51 …
risk of neutropenia during chemotherapy than C/T heterozygous patients (p= 0.02, χ²= 5.51 …